naltrexone has been researched along with Neoplasms in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.92) | 18.7374 |
| 1990's | 1 (1.96) | 18.2507 |
| 2000's | 9 (17.65) | 29.6817 |
| 2010's | 24 (47.06) | 24.3611 |
| 2020's | 15 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Cao, JL; Chen, R; Ding, L; Fei, YH; Guo, F; Jiang, Y; Liu, N; Liu, Y; Lu, C; Qi, J; Sui, Z; Wang, MM; Wang, W; Wang, X; Wang, Y; Wei, X; Wu, M; Xing, Y; Zhang, P; Zhang, Y | 1 |
| Fujita, Y; Hiruta, E; Imai, H; Ito, M; Kamiya, T; Koizuka, S; Kotake, M; Masuno, T; Matsuura, M; Minato, K; Mogi, J; Nishiba, H; Takei, S; Tanaka, H; Yamazaki, S | 1 |
| Abe, H; Fushimi, K; Inoue, R; Matsui, H; Sumitani, M; Uchida, K; Yasunaga, H | 1 |
| Hashimoto, S; Honda, K; Nakazawa, M; Takata, K | 1 |
| Dalgleish, AG; Liu, WM | 1 |
| Argente Navarro, MP; Belltall, A; Diaz-Cambronero, O; Eroles, P; Mazzinari, G | 1 |
| Akatori, H; Arakawa, K; Gondoh, E; Hamada, Y; Higashiyama, K; Inada, E; Iseki, M; Iwazawa, Y; Kuzumaki, N; Miyano, K; Mori, T; Narita, M; Sato, D; Shinohara, A; Suda, Y; Tanaka, K; Tezuka, H; Tsujimura, M; Yamashita, K; Yamauchi, T; Yoshida, S | 1 |
| Candy, B; Jones, L; Larkin, PJ; Stone, P; Vickerstaff, V | 2 |
| Ishizuka, Y; Kanbayashi, Y; Sawa, S; Shimizu, M; Uchida, M; Yabe, K | 1 |
| Shan, F; Wang, R; Zhang, Y | 1 |
| Aruga, E; Ikezawa, E; Kato, Y; Kobayashi, C; Osawa, G; Takagi, Y | 1 |
| Higurashi, T; Honda, Y; Ichikawa, Y; Imajo, K; Ishiki, H; Iwaki, M; Kato, T; Kessoku, T; Kobayashi, N; Kobayashi, T; Nakajima, A; Ogawa, Y; Ozaki, A; Saito, S; Taguri, M; Yamanaka, T; Yoneda, M; Yoshihara, T | 1 |
| Farnaghi, F; Gholami, N; Hassanian-Moghaddam, H; McDonald, R; Saberi, M; Zamani, N | 1 |
| Abd-Elsayed, A; Khajehdehi, N; Khan, JS; Kordbacheh, K; Liubchenko, K; Ma, F; Storey, M; Visnjevac, O; Visnjevac, T | 1 |
| Couto, RD; Fernandes, BJD | 1 |
| Handley, MK; Meng, Y; Qu, N; Shan, F; Wang, C | 1 |
| Boku, N; Katakami, N; Nakata, K; Narabayashi, M; Oda, K; Shinozaki, K; Suzuki, Y; Tauchi, K; Yokota, T | 1 |
| Arai, M; Boku, N; Harada, T; Katakami, N; Murata, T; Narabayashi, M; Shinozaki, K; Tada, Y; Tsutsumi, M; Yokota, T | 1 |
| Kosugi, K; Tanimoto, T; Yagi, Y | 1 |
| Katakami, N; Tada, Y; Yokota, T | 1 |
| Feng, J; Griffin, N; Li, Z; Shan, F; You, Y | 1 |
| Asonuma, S; Emi, Y; Fujii, M; Ikeda, M; Kajiwara, M; Kometani, T; Mori, M; Noda, Y; Ochiai, T; Shikada, Y | 1 |
| Beeker, A; Berkhof, J; Neefjes, ECW; Rhodius, CA; Ten Oever, D; van den Berg, HP; van der Vliet, HJ; van der Vorst, MJDL; van der Wijngaart, H; Verheul, HMW | 1 |
| Allingham, S; Brown, L; Clark, K; Currow, DC; Phillips, JL | 1 |
| Alexander, S; Dupuis, LL; Lau, E; Mattiussi, A; Rodrigues, A; Wong, C | 1 |
| Buhler, L; Icard, P; Lincet, H; Schwartz, L; Steyaert, JM | 1 |
| Indovina, P; Raffaeli, W | 1 |
| Baker, JN; Flerlage, JE | 1 |
| Kren, NP; McLaughlin, PJ; Zagon, IS | 1 |
| Atkins, JT; Janku, F; Karp, DD; Moss, J; Singleton, PA | 1 |
| Atkins, JT; Janku, F; Johnson, LK; Karp, DD; Moss, J; Singleton, PA | 1 |
| Ades, S; Ashikaga, T; Ji, Y; Kumar, S; Mori, M | 1 |
| Brown, N; Panksepp, J | 1 |
| Donahue, RN; McLaughlin, PJ; Zagon, IS | 1 |
| Berbari, J; Farah, B; Iskedjian, M; Iyer, S; Librach, SL; Wang, M | 1 |
| Byfieldt, N; Clark, K; Currow, DC; Dawe, M | 1 |
| Lissoni, P; Rovelli, F | 1 |
| Gatti, A; Sabato, AF | 1 |
| McLaughlin, PJ; Zagon, IS | 2 |
| Coulter, I; Coulter, SA; Favreau, JT; Gagne, J; Hardy, ML; Jungvig, LK; Morton, SC; Newberry, S; Ramirez, LR; Rohr, L; Roth, EA; Shekelle, P; Udani, J | 1 |
| Thomas, J | 1 |
| McLaughlin, PJ; Rahn, KA; Zagon, IS | 1 |
| Galasso, FL; Israel, RJ; Moehl Boatwright, ML; Portenoy, RK; Stambler, N; Thomas, J; Tran, D; Von Gunten, CF | 1 |
| Cannon, JT; Lewis, JW; Liebeskind, JC; Shavit, Y; Terman, GW | 1 |
| Levin, RJ; McLaughlin, PJ; Ohlsson-Wilhelm, BM; Roesener, CD; Verderame, MF; Zagon, IS | 1 |
| Allen, J; Billington, CJ; Kay, N; Moon, T; Morley, JE | 1 |
15 review(s) available for naltrexone and Neoplasms
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
Naltrexone at low doses (LDN) and its relevance to cancer therapy.
Topics: Humans; Naltrexone; Neoplasms | 2022 |
Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
Topics: Cell Proliferation; Humans; Naltrexone; Narcotic Antagonists; Neoplasms; Quaternary Ammonium Compounds; Receptors, Opioid | 2022 |
Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Topics: Adult; Analgesics, Opioid; Child; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Neoplasms; Opioid-Induced Constipation; Oxycodone; Palliative Care; Quaternary Ammonium Compounds; Substance Withdrawal Syndrome | 2022 |
Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
Topics: Animals; Enkephalin, Methionine; Humans; Naltrexone; Narcotic Antagonists; Neoplasms | 2019 |
Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures.
Topics: Animals; Cell Culture Techniques; Humans; Models, Animal; Naltrexone; Narcotic Antagonists; Neoplasms; Prospective Studies; Retrospective Studies | 2021 |
Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer.
Topics: Antineoplastic Agents; Cell Proliferation; Humans; Naltrexone; Narcotic Antagonists; Neoplasms | 2021 |
Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy.
Topics: Animals; Disease Models, Animal; Humans; Naltrexone; Narcotic Antagonists; Neoplasms; Receptors, Opioid | 2021 |
Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Topics: Constipation; Defecation; Female; Gastrointestinal Agents; Humans; Intestinal Diseases; Male; Nalbuphine; Naloxone; Naltrexone; Narcotic Antagonists; Neoplasms; Opioid-Related Disorders; Oxycodone; Palliative Care; Piperidines; Quaternary Ammonium Compounds; Randomized Controlled Trials as Topic; Receptors, Opioid, mu | 2018 |
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
Topics: Analgesics, Opioid; Animals; Autoimmunity; Crohn Disease; Drug Dosage Calculations; Humans; Immunologic Factors; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Neoplasms; Off-Label Use; Receptors, Opioid; Substance Abuse Treatment Centers | 2018 |
The mu opioid receptor: A new target for cancer therapy?
Topics: Animals; Humans; Mice; Molecular Targeted Therapy; Naltrexone; Narcotic Antagonists; Neoplasms; Quaternary Ammonium Compounds; Receptors, Opioid, mu | 2015 |
Principles of psychoneuroendocrinoimmunotherapy of cancer.
Topics: 5-Methoxytryptamine; Antineoplastic Combined Chemotherapy Protocols; Cannabinoid Receptor Modulators; Humans; Immunotherapy; Interleukin-2; Melatonin; Naltrexone; Neoplasms; Neurosecretory Systems | 2012 |
Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone.
Topics: Analgesics, Opioid; Constipation; Humans; Naltrexone; Narcotic Antagonists; Neoplasms; Pain; Palliative Care; Quaternary Ammonium Compounds | 2012 |
Cancer-related constipation.
Topics: Alprostadil; Constipation; Fatty Acids; Gastrointestinal Agents; Humans; Indoles; Lubiprostone; Naltrexone; Narcotic Antagonists; Neoplasms; Piperidines; Quaternary Ammonium Compounds; Serotonin Receptor Agonists | 2007 |
7 trial(s) available for naltrexone and Neoplasms
| Article | Year |
|---|---|
Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study.
Topics: Analgesics, Opioid; Clinical Trials, Phase II as Topic; Defecation; Humans; Japan; Magnesium Oxide; Naltrexone; Neoplasms; Opioid-Induced Constipation; Proof of Concept Study; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic | 2020 |
Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Constipation; Defecation; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neoplasms; Opioid-Related Disorders | 2017 |
Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Topics: Adult; Aged; Analgesics, Opioid; Constipation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Naltrexone; Neoplasms; Opioid-Related Disorders; Pain Management; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2017 |
Methylnaltrexone for opioid-induced constipation in pediatric oncology patients.
Topics: Adolescent; Analgesics, Opioid; Child; Child, Preschool; Constipation; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Neoplasms; Pain; Quaternary Ammonium Compounds; Retrospective Studies | 2013 |
Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.
Topics: Adult; Aged; Analgesics, Opioid; Constipation; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Laxatives; Male; Middle Aged; Naltrexone; Neoplasms; Quaternary Ammonium Compounds; Receptors, Opioid, mu | 2016 |
Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Constipation; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neoplasm Staging; Neoplasms; Prognosis; Quaternary Ammonium Compounds | 2017 |
Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neoplasms; Pain; Pain Measurement; Quaternary Ammonium Compounds; Terminal Care | 2008 |
29 other study(ies) available for naltrexone and Neoplasms
| Article | Year |
|---|---|
Stimulating TRPM7 suppresses cancer cell proliferation and metastasis by inhibiting autophagy.
Topics: Apoptosis; Autophagosomes; Autophagy; Cell Proliferation; Clozapine; Humans; Lysosomes; Naltrexone; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Protein Serine-Threonine Kinases; R-SNARE Proteins; Signal Transduction; TRPM Cation Channels; Zinc | 2022 |
Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study.
Topics: Analgesics, Opioid; Constipation; Humans; Naltrexone; Neoplasms; Opioid-Induced Constipation; Retrospective Studies | 2021 |
Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: A nationwide retrospective cohort study in Japan.
Topics: Analgesics, Opioid; Constipation; Delirium; Humans; Ileus; Incidence; Japan; Naltrexone; Neoplasms; Opioid-Induced Constipation; Retrospective Studies | 2022 |
Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan.
Topics: Analgesics, Opioid; Cancer Pain; Constipation; Humans; Japan; Naltrexone; Narcotic Antagonists; Neoplasms; Opioid-Induced Constipation; Product Surveillance, Postmarketing; Prospective Studies | 2022 |
Possible mechanism for improving the endogenous immune system through the blockade of peripheral μ-opioid receptors by treatment with naldemedine.
Topics: Analgesics, Opioid; Animals; beta-Arrestins; Immune System; Mice; Morphine Derivatives; Naltrexone; Neoplasms; Receptors, Opioid, mu; Toll-Like Receptor 4 | 2022 |
Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
Topics: Analgesics, Opioid; Constipation; Gastrointestinal Agents; Humans; Morphinans; Naltrexone; Narcotic Antagonists; Neoplasms; Opioid-Induced Constipation; Quality of Life; Retrospective Studies | 2022 |
Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Diarrhea; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neoplasms; Palliative Care; Receptors, Opioid, mu; Retrospective Studies | 2020 |
A study of the effectiveness of naltrexone in preventing recurrence of methadone poisoning in opioid-naive children.
Topics: Adolescent; Aftercare; Analgesics, Opioid; Child; Child, Preschool; Female; Hospitalization; Humans; Infant; Intensive Care Units; Iran; Male; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Neoplasms; Patient Discharge; Poisoning; Recurrence; Retrospective Studies | 2021 |
Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Topics: Analgesics, Opioid; Constipation; Humans; Naltrexone; Narcotic Antagonists; Neoplasms | 2018 |
Reply to Y. Yagi et al.
Topics: Analgesics, Opioid; Constipation; Humans; Naltrexone; Neoplasms | 2018 |
[A New Twist on the Administration of Naldemedine for Opioid-Induced Constipation in an Outpatient].
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Constipation; Diarrhea; Female; Humans; Male; Middle Aged; Naltrexone; Neoplasms; Outpatients | 2018 |
Optimal treatment of opioid induced constipation in daily clinical practice - an observational study.
Topics: Aged; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Laxatives; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neoplasms; Oxycodone; Pain Management; Prospective Studies; Quaternary Ammonium Compounds; Retrospective Studies; Surveys and Questionnaires | 2019 |
A Response to: Challenges in Recruiting Patients to a Controlled Feasibility Study of a Drug for Opioid-Induced Constipation: Lessons From the Population With Advanced Cancer.
Topics: Analgesics, Opioid; Constipation; Feasibility Studies; Humans; Naltrexone; Narcotic Antagonists; Neoplasms | 2019 |
Metabolic treatment of cancer: intermediate results of a prospective case series.
Topics: Adult; Aged; Citrates; Compassionate Use Trials; Female; Humans; Male; Middle Aged; Naltrexone; Neoplasms; Prospective Studies; Thioctic Acid; Vitamin B Complex | 2014 |
Low-dose naltrexone to prevent intolerable morphine adverse events: a forgotten remedy for a neglected, global clinical need.
Topics: Analgesics, Opioid; Chronic Pain; Dose-Response Relationship, Drug; Humans; Morphine; Naltrexone; Narcotic Antagonists; Neoplasms | 2015 |
Methylnaltrexone for Opioid-Induced Constipation in Children and Adolescents and Young Adults with Progressive Incurable Cancer at the End of Life.
Topics: Adolescent; Analgesics, Opioid; Child; Child, Preschool; Constipation; Double-Blind Method; Female; Humans; Infant; Male; Medical Audit; Naltrexone; Narcotic Antagonists; Neoplasms; Quaternary Ammonium Compounds; Retrospective Studies; Terminally Ill; Young Adult | 2015 |
Mutations in the opioid growth factor receptor in human cancers alter receptor function.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; COS Cells; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Mutation, Missense; Naltrexone; Narcotic Antagonists; Neoplasms; Receptors, Opioid; Transfection | 2015 |
Low-dose naltrexone for disease prevention and quality of life.
Topics: Cytokines; Dose-Response Relationship, Drug; Humans; Inflammation; Models, Immunological; Naltrexone; Narcotic Antagonists; Neoplasms; Quality of Life | 2009 |
Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
Topics: Cell Line, Tumor; Cell Proliferation; Enkephalin, Methionine; Gene Expression Regulation, Neoplastic; Humans; Naltrexone; Narcotic Antagonists; Neoplasms; Receptors, Opioid; RNA Interference; RNA, Messenger; Signal Transduction | 2009 |
Methylnaltrexone in the treatment of opioid-induced constipation in cancer patients receiving palliative care: willingness-to-pay and cost-benefit analysis.
Topics: Adolescent; Adult; Age Distribution; Analgesics, Opioid; Constipation; Consumer Behavior; Cost of Illness; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neoplasms; Ontario; Pain; Palliative Care; Patient Acceptance of Health Care; Quaternary Ammonium Compounds; Sex Distribution; Socioeconomic Factors; Treatment Outcome; Young Adult | 2011 |
Treating constipation in palliative care: the impact of other factors aside from opioids.
Topics: Aged; Analgesics, Opioid; Constipation; Female; Humans; Laxatives; Male; Medical Records; Middle Aged; Naltrexone; Narcotic Antagonists; Neoplasms; New South Wales; Outcome Assessment, Health Care; Palliative Care; Quaternary Ammonium Compounds; Risk Factors | 2012 |
The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Diabetes Complications; Enkephalin, Methionine; Epithelium; Homeostasis; Humans; Lymphocytes; Naltrexone; Narcotic Antagonists; Neoplasms; Receptors, Opioid; Wound Healing | 2012 |
Opioids and the apoptotic pathway in human cancer cells.
Topics: Annexin A5; Apoptosis; Cell Adhesion; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Etorphine; Growth Substances; Humans; In Situ Nick-End Labeling; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Necrosis; Neoplasms; Tumor Cells, Cultured | 2003 |
Best-case series for the use of immuno-augmentation therapy and naltrexone for the treatment of cancer.
Topics: Complementary Therapies; Female; Humans; Immunotherapy; Interviews as Topic; Male; Naltrexone; Neoplasms; Quality of Life; Research; Surveys and Questionnaires | 2003 |
Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells.
Topics: Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Physiological Phenomena; Chemotaxis; Dose-Response Relationship, Drug; Enkephalin, Methionine; Humans; Membrane Glycoproteins; Naltrexone; Narcotic Antagonists; Neoplasm Invasiveness; Neoplasms; Opioid Peptides | 2007 |
Intrinsic mechanisms of pain inhibition: activation by stress.
Topics: Adaptation, Physiological; Adrenalectomy; Anesthesia; Animals; Brain Stem; Conditioning, Psychological; Electroshock; Endorphins; Histamine; Humans; Hypophysectomy; Immunosuppression Therapy; Naltrexone; Neoplasms; Nociceptors; Pain; Pentobarbital; Rats; Stress, Physiological | 1984 |
Cancer pain remedy wins orphan drug status.
Topics: Blood-Brain Barrier; Constipation; Drug Therapy, Combination; Humans; Morphine; Naltrexone; Narcotic Antagonists; Nausea; Neoplasms; Orphan Drug Production; Pain; Quaternary Ammonium Compounds; United States; United States Food and Drug Administration | 1996 |
Opioid growth factor regulates the cell cycle of human neoplasias.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Colonic Neoplasms; DNA Replication; Enkephalin, Methionine; Head and Neck Neoplasms; Humans; Naltrexone; Narcotic Antagonists; Neoplasm Proteins; Neoplasms; Pancreatic Neoplasms; Receptors, Opioid; Resting Phase, Cell Cycle; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Endorphins, immune function, and cancer.
Topics: Endorphins; Humans; Interferons; Killer Cells, Natural; Naltrexone; Neoplasms; Stress, Physiological | 1985 |